The Immunohistochemically Estimation of CD63 in Iraqi Patients with Gastric Cancer

Main Article Content

Raghad Khalid Mwafaq
https://orcid.org/0000-0002-8537-986X
Amal Khudair Abbas
Leith Abdul Hussein Abdullah
Kifah Hamdan Abdul Ghafour
https://orcid.org/0000-0002-0996-7221

Abstract

CD63 is -one of the tetraspanin family proteins, which are regarded as: hallmark exosomal markers because it is absent from other types of vesicles. It is expressed in the cell membrane of cancer cells, and cytoplasm of stromal cells. Objective: To assess CD63 expression in gastric cancer (GC) patients, and detected if it could be used as a predictive marker. Furthermore, the current study aimed to find the correlation between CD63 expression and clinicopathological parameters as: gender, age, invasion depth, histopathological type, involvement of lymph nodes, grade and stages of GC (TNM). The current study is a retrospective study in the period time from (2018 to-2020); 50 randomly patients formalin-fixed paraffin embedded blocks (FFPE) of stomach tissue (10 cases normal tissue without GC as control, and 40 patients with GC) with its reports and diagnosis were collected from Pathology Department of the Gastroenterology and Hepatology Teaching Hospital and some private hospitals. The histological sections were stained by hematoxylin and eosin stain (H&E), and immunohistochemistry (IHC) stain for CD63. Statistical analysis accomplished by SPSS system at (P ≤ 0.05). This study indicated that there were  significant differences between control group, and patients group in the expression of CD63, also there was a significant correlation between CD63 expression, and histopathological subtype, invasion depth, involvement of lymph node, and stages in patients, whereas there was a non- significant association between the age, grade, and gender of patients, and the expression of CD63.This result indicates that CD63 could be a good prospective marker in Iraqi cancer patients.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Mwafaq RK, Abbas AK, Abdullah LAH, Abdul Ghafour KH. The Immunohistochemically Estimation of CD63 in Iraqi Patients with Gastric Cancer . Baghdad Sci.J [Internet]. 2022 Oct. 1 [cited 2022 Nov. 30];19(5):0932. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/6272
Section
article

References

Gao J P, Xu W, Liu W T, Yan M, Zhu Z G. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J. Gastroenterol. 2018 Jun28; 24 (24): 2567–2581.

Hussain A A M, Lafta R K. Cancer Trends in Iraq 2000–2016. Oman Med J. 2021 Jan31; 36 (1): e219.

Thrift A P, El-Serag H B. Burden of gastric cancer. Clin Gastroenterol.Hepatol. 2020 Jul 27; 18 (3): 534–542.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histoclinical classification. Acta Pathol Microbiol Scand.1965 Jan31; 64:31–49.

Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020 Jun 4; 21(11): 4012.

Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther.2020 Aug 5; 5:145.

Fu M, Gu J, Jiang P, Qian H. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol. Cancer. 2019 Mar15; 18:41.

Maecker HT, Todd SC, Levy S.The tetraspanin superfamily: molecular facilitators. FASEB J. 1997 May1; 11(6):428-42.

Stuffers S, Sem Wegner C., Stenmark H, Brech A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic.2009 Jul 10; 10 (7):925–937.

Lotvall J., Hill A F, Hochberg F, Buzas E I, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles. 2014 Dec 22; 3: 26913.

Kowal J, Arras G, Colombo M, Jouve M, Morath J P, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016 Feb 23; 113 (8): E968–E977.

Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003Nov; 19:397-422.

Kwon MS, Shin SH, Yim SH, Lee KY, Kang HM, Kim TM, et al.CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer. 2007 Mar 12; 57(1):46-53.

Miki Y, Yashiro M, Okuno T, Kuroda K, Togano S, Hirakawa K, et al. Clinico-pathological significance of exosome marker CD63 expression on cancer cells and stromal cells in gastric cancer. PLoS One.2018 Sep 17; 13 (9): e0202956.

Suvarna S K, Layton C, Bancroft J D. Bancroft’s theory and practice of histological techniques 8th ed. Elsevier; 2019.637p.

Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014 Mar 13; 40 (6):692-700.

Liu Y, Zhang Y, Zhao Y, Gao D. High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer. Oncol Lett.2016 Sep 22; 12 (5): 3825–3835.

Hermiz RS, Hussain AG, Qasim JG. Immunohistochemical expression of p53 in gastric carcinoma (A clinic pathological study). Iraqi J.Med. Sci. 2008 Jun8; 6 (2): 77-89.

Raziq AH, Haj SM, Arif SH. Gastric Malignancies and the Trend of Gastric Carcinoma in Duhok City-Iraq. Med J Babylon.2017 May10; 14 (1): 162 – 168.

Saeed NAH. Epstein Barr Virus and P53 gene expression correlation with gastric adenocarcinoma patients in Baghdad city. IJB. 2016 Feb14; 15 (1): 73-82.

Saeed NAH., Ali LQ, Zabbon AA, Saeed ZA. Expression of tumor suppressor P53 correlation with gastric adenocarcinoma patients by using immunohistochemical assay. World J. pharm.Res.2018 Jun10; 7 (12): 125-132.

Al-Omran B, Ansari N. Gastric cancer in Bahrain: A retrospective study of histologically Confirmed tumor between 2001 and 2007 from the two main Bahraini referral hospitals. J. Pathol.2015 Oct 20; 5:129-136.

Kassim A, Thabet S, Al-Fakih S, Alqobaty M. Clinical and histopathological charactristic Gastric adenocarcinoma in Yemeni patients: A 2 years prospective study. OALib. Journal. 2018 Dec 25; 5 (12): 5075-5086.

Lou L, Wang L, Zhang Y, Chen G, Lin L, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the global burden of disease study 2017. Br Med J. 2020 Dec 19; 10 (1):e033323.

Li H, Wei Z, Wang C, Chen W. Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database. J Gastrointest Surg.2020 Aug 25; 24 (8):1747–1757.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar1; 136 (5):E359-386.

Radkiewicz C, Johansson A L V, Dickman P W, Lambe M, Edgren G. Sex differences in cancer risk and survival: A Swedish cohort study. Eur J Cancer. 2017 Oct 1; 84: 130-140.

Camargo M C, Goto Y, Zabaleta J, Morgan D R. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol. Biomark. Prev. 2012 Jan 1; 21(1):20–38.

Xie S H, Lagergren J. The Male Predominance in Esophageal Adenocarcinoma. Clinical gastroenterology and hepatology: the official clinical practice journal of the American gastroenterological association. Clin Gastroenterol Hepatol. 2016 Mar1; 14 (3): 338–347.

Lafta SHA, Al Faisal AH. Association of Helicobacter Pylori infection and gastric cancer. IJB.2017 Sep 25; 16 (1): 1-9.

Zeeneldin A A, Ramadan H, El-Gammal M M, Magdy M. Gastric carcinoma at Tanta cancer center: A comparative retrospective clinicopathological study of the elderly versus the non-elderly. J Egypt Natl Cancer Inst. 2014 May 17; 26 (3): 127-137.

Alahmadi R, Hamour O, Al- Enizi, H, Tashkandi A. Incidence of gastric carcinoma at king faisal specialist Hospital- Jeddah Saudi Arabia: A hospital-based study. Int J Mol Med.2016 Apr1; 3 (2):606-611.

Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed. Gastrointest Endosc. 2016 Mar3; 84(1):18-28.

De B, Rhome R, Jairam V, Ozbek U, Holcombe R F, Buckstein M. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer. 2018 Apr 24; 21(6): 889–899.

Al-obaidi AB, Abdulhassan BA, Hanna DB, Kareem NM , Shamran H A. Detection of Epstein–Barr Virusand JC Polyomavirus in Gastric Cancer Tissue by Quantitative Real Time PCR. Med Leg Update.2020 Nov 18; 20 (4): 751-756.

Mohammed M R, Raziq AH. Survival related factors in gastrectomy specimens. A study of 65 cases in Duhok city-Iraq. Duhok Med J. 2021Apr 27; 15(1): 58-68.

Piazuelo M B, Correa P. Gastric cancer: Overview. Colomb Med. 2013 Sep 30; 44 (3):192-201.

Marques-Lespier J M, Gonzalez-Pons M, Cruz-Correa M. Current Perspectives on Gastric Cancer. Gastroenterol Clin North Am. 2016 Sep 1; 45(3):413–428.

Cisło M, Filip A A, Offerhaus G J A, Ciseł B, Rawicz-Pruszynski K, Skierucha M, et al. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. Oncotarget. 2018 Apr 10; 9 (27): 19427-19442.

Badary D M, Abdel-Wanis ME, Hafeze M Z, Aboulhagad NA. Immunohistochemical analysis of PTEN, HER2/neu, and Ki67 expression in patient with gastric cancer and their association with survival. Pathophysiology.2017 Jun2; 24 (2):99-106.

Al-Kaptan IAH. Uses of CD31 monoclonal antibody for the assessment of Angiogenesis as a prognostic factor in Gastric Adenocarcinoma. J. Fac. Med. -Baghdad.2005 Jun 1; 47 (1): 51-59.

Awad H A, Hajeer MH, Abulihya MW, Al-Chalabi MA, AL- Khader AA. Epidemiologic characteristic of gastric malignancies among Jordan University Hospital patients. Saudi Med. J.2017 Aug 2; 38 (9): 965-967.

Phan DAT, Nguyen VT, Hua TNH, Ngo Q D, Doan TPT, Nguyen ST, et al. HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient. J Pathol Transl Med.2017 Jun 19; 51 (4): 396-402.

Braga-Neto MB, Carneiro J G, Barbosa A M C, Silva I S, Maia D C, Maciel FS, et al. Clinical characteristics of distal gastric cancer in young adults from Northeastern Brazil. BMC Cancer.2018 Feb 5; 18 (1):131.

Abdulla AR, Ali HM, Al-Rawaq KJ, Ibraheem AN. IL-10 serum level estimation in Iraqi colorectal and gastric cancer patients. J. Fac. Med. Baghdad. 2012 Jul 1; 54 (2): 167-171.

Abdul Jabar SH, Al- Faisal AHM. The correlation between KRAS mutation and H. pylori in gastric cancer patients. IJB.2017 Oct 10; 16 (3): 82-93.

Ashour HJ, Al-Bakri NA, Abdul Ghafour KH. The Immunohistochemical Assessment of Muc5ac in Patients with Gastric Carcinoma (Gc) in Iraq. Iraqi J Sci.2019 Mar 25; 60 (3): 460-468.

Abdel-Salam RA, El-Hawary A, Mohamed MA, Gamil T. Immunohistochemical expression of Her2/neu in gastric carcinomas in Egyptian patients. J Clin Pathol Diagn.2018 Jan 8; 1(1):1–6.

Harras HF, Mowafy SE.CDX2 and cyclooxygenase-2 immunohistochemical expression in gastric carcinoma: relationship with clinicopathological features. Egypt J Pathol.2019 Apr 30; 39 (1):123-30.

Alvarado-Cabreroa I, Gil-Hernandezb S, Ruelas-Pereac A, Villaverde-Rodriguezc D. Immunohistochemical assessment of HER2 expression in gastric cancer. A clinicopathologic study of 93 cases. Cir Cir. Nov-Dec.2017 Jan 6; 85(6):504-509.

Raj N, Verma D, Kumar A, Rai P, Rao RN. HER2Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma. Discoveries (Craiova). 2018 Dec 31; 6(4): e83.

Gharsalli T, Bouazzi H, Aiwasiyah B, Sassi M, Sriha B. HER2-Neu Gene Testing in Gastric Cancer by Immunohistochemistry in Tunisian Patient’s Samples. J Cancer Diagn.2017 Feb 27; 2(1): 110.

Zhang W, He D, Chen D, Li T, Chen X, Yang K, et al. Comparison between superficial muscularis propria and deep muscularis propria infiltration in gastric cancer patients. Medicine (Baltimore). 2016 Jul 15; 95(29): e4165.

Feng LW, Li J, Liang LF, Guo QQ, Li J, Wu J, et al. A Predictive Scoring System Based on Inflammatory and Tumor Markers for Gastric Cancer Patients Undergoing Curative Resection. Cancer Manag Res.2020 May 26; 2020 (12): 3937–3948.

Li J, Pu K, Li C, Wang Y, Zhou Y. A Novel Six-Gene-Based Prognostic Model Predicts Survival and Clinical Risk Score for Gastric Cancer. Front. Genet. 2021 Feb 22; 12:615834.

Katai H, Ishikawa T, Akazawa K, Isobe, Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018 Apr17; 21:144–154.

Silva FDA, Pereira MA, Ramos MFKP, Ribeiro-Junior U, Zilbersteini B, Cecconello V, et al. Diasgastrectomy in octogenarians with gastric cancer: Is it feasible. ABCD Arq Bras Cir Dig. 2020 Jan 25; 33(4): e1552.

Waddingham W, Graham D, Banks M, Jansen M.The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. F1000Res. 2018 Jun 8; 7(F1000 Faculty Rev):715.

Yoo S, Chen Q, Wang L, Wang W, Chakravarthy A, Busuttil R. Molecular and cellular heterogeneity of gastric cancer explained by methylation-driven key regulators. bioRxiv.2020 Jan28; 920744.

Grunwald B, Harant V, Schaten S, Fruhschutz M, Spallek R, Hochst B, et al. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver. Gastroenterology. 2016 Aug 6; 151 (5): 1011–1024.

Aaberg-Jessen C, Sorensen MD, Matos A, Moreira JM, Brunner N, Knudsen A, et al. Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas. BMC Cancer. 2018 Mar9; 18: 270.

Takino T, Miyamori H, Kawaguchi N, Uekita T, Seiki M, Sato H. Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Co. 2003 Apr25; 304(1):160-166.

Radford K J, Thorne R F, Hersey P. CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Co. 1996 May 6; 222(1):13-8.

Seubert B, Cui H, Simonavicius N, Honert K, Schafer S, Reuning U, et al. Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization. Int J Cancer. 2015 May 15; 136 (10):2304–2315.

Mohammed S W, Khashman B M, Khalaf N F, Ismeeal M C, Al-Malkey M K. Immunohistochemical Expression of P16 Protein and TGF β1 in Mice Liver Exposed to Fumonisin B1. Baghdad Sci .J [Internet]. 2020May10;17(2):0401.

Journal BS. The Prognostic Value of some Epithelial-Mesenchymal Transition Markers and Metastasis-Related Markers in Human Transitional Cell Carcinoma of the Bladder: May Khaleel Ismael. Baghdad Sci.J .2018Sep.13;15(3):0244.